The availability and increasing popularity of direct-to-consumer genetic testing for the presence of an APOE4 allelle led the Alzheimer's Foundation of America Medical, Scientific and Memory Screening Advisory Board to identify three critical areas for attention: 1) ensure consumer understanding of test results; 2) address and limit potential negative consequences of acquiring this information; and 3) support linking results with positive health behaviors, including potential clinical trial participation. Improving access to appropriate sources of genetic counseling as part of the testing process is critical and requires action from clinicians and the genetic testing industry. Standardizing information and resources across the industry should start now, with the input of consumers and experts in genetic risk and health information disclosure. Direct-to-consumer testing companies and clinicians should assist consumers by facilitating consultation with genetic counselors and facilitating pursuit of accurate information about testing.
|Number of pages||3|
|Journal||Journal of Alzheimer's Disease|
|State||Published - 2018|
Bibliographical notePublisher Copyright:
© 2018 - IOS Press and the authors. All rights reserved.
- genetic risk
- genetic testing
- late-onset Alzheimer's disease
ASJC Scopus subject areas
- Neuroscience (all)
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health